Építés alatt – nem éles oldal
Belépés
Résztvevőt keres itt: Brazília4. fázis

Safety and Efficacy of Decentralized HCV Treatment vs Standard-of-Care in Rio de Janeiro (Brazil)

A legfontosabb adatok

Ki végzi
Oswaldo Cruz Foundation
Hol
Rio de Janeiro (Brazília)Mind a 2 helyszín megnézése
Azonosító
Állapot
Toboroz
Fázis
4. fázis
Résztvevők
30 000 fő, tervezett
Kezdés
2022. júl. 4.
Várható befejezés
2026. dec. 31.
A vizsgálat típusa
Beavatkozással járó, 6 csoportAz egyik csoport egy már használt kezelést kap, összehasonlításként.
A vizsgált kezelések
  • Specialist - Epclusa 400Mg-100Mg Tablet
  • Non- specialist - Epclusa 400Mg-100Mg Tablet
  • HCV Self-Testing kit (Ora-Quick HCV ST or Wond-Foo HCV ST)
  • HCV Rapid Testing kit
A regiszteradat frissítve
2026. augusztus 17.

Ki vehet részt

MI-összefoglaló

A vizsgálat saját részvételi feltételeiből. Gép olvasta ki az oldalon álló regiszterszövegből, ezért tévedhet. Hogy ki vehet részt, azt a lenti regiszterszöveg és a vizsgálat csapata dönti el.

The trial is looking for adults aged 18 to 79 who visit a basic health care unit in Rio de Janeiro, for hepatitis C screening. People found to have active hepatitis C can join a treatment study comparing care by family doctors with care by specialists.

Életkor
18 to 79 years
Nem
All sexes
A betegség stádiuma
Screening part: anyone in the age range. Treatment part: active or long-term (chronic) hepatitis C. People with signs of advanced liver scarring that no longer works well cannot join.
Korábbi kezelés
Treatment part: people who regularly take medicines that may interact with SOF/VEL, or medicines that weaken the immune system, cannot join.
Biomarker vagy leletérték
Treatment part: a positive HCVab test and detectable HCV-RNA (the virus is found in the blood).

A részvétel fő kizáró okai

  • An illness needing urgent treatment, or a sudden illness with fever such as COVID-19, Dengue, Zika or Chikungunya
  • Pregnancy (positive urine test) or breastfeeding, for the treatment part
  • Also having HBV (hepatitis B) or HIV, for the treatment part
  • Active cancer, a solid organ transplant, or a severe sudden illness
  • Fluid in the belly, liver-related confusion, or bleeding in the gut within the last 12 weeks

A regiszter feltételei, szó szerint

Mind a 13 feltétel megnézéseKevesebb

Ki vehet részt

  • Age between 18-79 years-old
  • Age between 18 and 79 years old
  • Presence of active/chronic hepatitis C, defined by a positive HCVab test and detectable HCV-RNA

Ki nem vehet részt

  • Regular use of medications with potential drug interactions or contraindication for co-administration with SOF/VEL
  • Presence of a disease that need urgent/emergency treatment and/or acute febrile illness, such as COVID-19, Dengue, Zyca virus infection or Chikungunya
  • Co-infection with HBV or HIV
  • Presence of severe acute illness, active neoplasia, solid organ transplant, or use of immunosuppressive medications
  • Presence of clinical signs of decompensated liver cirrhosis (ascites, hepatic encephalopathy, report of a recent episode of gastrointestinal bleeding within the last 12 weeks)
  • Children and adolescents (< 18 years old)
  • Lack of capacity to sign the informed consent or refuse to participate; Study II
  • Pregnancy, defined by a positive β-HCG urinary test
  • Lactating individuals

Egyéb feltételek

  • Study I and Sub-Study

A fő feltételek kérdésként

Magadról válaszolj. Ez nem döntés: hogy részt vehetsz-e, azt csak a vizsgálat csapata mondhatja meg.

  • 18 és 79 év között vagy?

Ez a vizsgálat jelenleg itt érhető el: Brazília.

  • Evandro Chagas National Institute of Infectious DiseasesRio de Janeiro, BrazíliaContact: Hugo Perazzo, PhDRésztvevőt keres
  • Hugo PerazzoRio de Janeiro, BrazíliaContact: Hugo Perazzo, PhDRésztvevőt keres

A vizsgálatról

Mit akar kideríteni a vizsgálat

Up to 650,000 people in Brazil are living with chronic hepatitis c virus (HCV) infection. Hepatitis C is a silent disease, and up to 20% of cases can progress to liver cirrhosis and its complications. Rapid tests for diagnosis of HCV infection and non-invasive methods for detecting liver cirrhosis are available in the Brazilian Public Health System. Additionally, safe and highly effective drugs (direct-acting antivirals, DAAs) have been delivered for free for hepatitis C treatment by the Brazilian Unified Health System (Sistema Único de Saúde, SUS) since 2015. Sustained virological response (SVR) rates with DAAs in studies conducted in Brazil and Latin America were higher than 90%. Despite the availability of rapid tests for early diagnosis and effective drugs, the HCV continuum of care remains deficient in Brazil. It is estimated that only 10% of individuals known to have hepatitis C achieve HCV cure (SVR). This is explained by multiple barriers from diagnosis to treatment access, such as low rates of population screening (HCVST are not available in Brazil) and few available slots in tertiary centers for hepatitis C treatment by specialists. International studies have described that SVR rates by simplified hepatitis C treatment performed by non-specialists in the Primary Care System were similar to those treated in tertiary centers by specialists (standard-of-care). However, the optimal strategy for managing hepatitis C within the Brazilian-SUS remains unclear.This project aims to evaluate the improve of the HCV continuum of care by a implementation of a test-and-treat strategy in the Primary Care System in Brazil. The project consists of two parallel studies (and a sub-study).

A teljes eredeti leírásKevesebb

The project consists of two parallel studies (and a sub-study). Study I is a population-based cross-sectional screening study using rapid tests to determine the prevalence of HCV infection in people attending a Basic Health Care Unit. The sub-study associated with Study I is a cross-sectional study to assess the usability of a self-test for the detection of HCV antibodies in oral fluid (participants included in Study I). Study II is a phase IV open-label randomized clinical trial to evaluate the non-inferiority of simplified and decentralized hepatitis C treatment ("Simplified-and-Decentralized (SD) HCV treatment"; experimental arm) compared to specialist reference treatment ("Standard-of-Care (SC) HCV treatment"; control arm) within the SUS.

A vizsgálat 6 csoportja

  • Study INincs vizsgálati kezelés, összehasonlításként

    Study I is a population-based cross-sectional screening study (n=30,000 individuals) using rapid tests to determine the prevalence of HCV infection in people attending a Basic Health Care Unit.

  • Substudy INincs vizsgálati kezelés, összehasonlításként

    The sub-study associated with Study I is a cross-sectional study to assess the usability of a self-test for the detection of HCV antibodies in oral fluid (n=1,500 participants included in Study I).

  • Study II - SpecialistMár használt kezelés, összehasonlításként

    HCV standard-of-care treatment"; control arm. Participants randomized for the Standard-of-Care HCV treatment arm will be referred for the usual treatment of hepatitis C by specialists (hepatologists and/or infectious disease specialists) at a tertiary center \[INI/FIOCRUZ or Hospital Universitário Clementino Fraga Filho (HUCFF/UFRJ)\]. Participants will be treated with the pan-genotypic therapeutic regimen "single-pill daily," at a fixed dose and duration: sofosbuvir/velpatasvir 400/100 mg (Epclusa, Gilead Sciences, USA) 1 tablet orally per day for 12 weeks.

    Kezelés: Specialist - Epclusa 400Mg-100Mg Tablet

  • Study II - Non SpecialistMár használt kezelés, összehasonlításként

    Decentralized hepatitis C treatment ("DS HCV treatment"; experimental arm).Participants randomized for the "Decentralized-and-Simplified HCV treatment" (DS HCV treatment) arm will be referred for simplified treatment of chronic hepatitis C at the Primary Health Care unit where participants were included in Study I and are registered for care. The treatment will be conducted by a non-specialist physician (general practitioner or family doctor) after training provided by a specialist (hepatologist) on the treatment of patients with hepatitis C using DAAs. Participants will be treated with a pan-genotypic therapeutic regimen, a fixed-dose, single-pill daily: sofosbuvir/velpatasvir 400/100 mg (Epclusa, Gilead Sciences, USA), 1 tablet orally per day for 12 weeks.

    Kezelés: Non- specialist - Epclusa 400Mg-100Mg Tablet

  • Sub-Study III - HCV Self-testing ArmMár használt kezelés, összehasonlításként

    People randomized for this arm will receive an HCV self-testing kit (oral fluid or blood-based) for HCV testing

    Kezelés: HCV Self-Testing kit (Ora-Quick HCV ST or Wond-Foo HCV ST)

  • Sub-Study III - Standard-of-care: Rapid HCV Testing ArmPlacebo, összehasonlításként

    People randomized for this arm will receive a prescription for HCV testing

    Kezelés: HCV Rapid Testing kit

Kérdések a vizsgálat csapatának

  1. Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
  2. Megtérítik az utazási költséget?
  3. Megtarthatom a saját orvosomat?
  4. Mi történik, ha ki akarok lépni?

Contact the study team: see the registry record → Contacts and Locations

Oldal nyomtatása az orvosomnak

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
Hivatalos cím
Randomized Open-label and Non-inferiority Clinical Trial to Evaluate the Safety, Adherence, and Cost-effectiveness of Simplified and Decentralized Hepatitis C Treatment in Primary Health Care Compared to Standard-of-care in the Brazilian Public Health System
MI-összefoglaló
A vizsgálat saját részvételi feltételeiből. Gépi kiolvasás: 2026. november 14.
Kérdések a feltételekről
Forrás: NCT06306300: ki vehet részt
A regiszteradat frissítve
2026. augusztus 17.